This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Dewey K. Ziegler, MD; David J. Ellis, MD, PhD

Arch Neurol. 1985;42(6):582-584.

Abstract
• Naproxen sodium is an inhibitor of platelet aggregation and prostaglandin synthesis and is also a potent anti-inflammatory agent. Because of these properties, it was evaluated in prophylaxis of migraine by a double-blind, placebo-controlled crossover study in 34 patients. Drug "preference" and therapeutic effect were rated by both patient and investigator. Overall, both preferred drug over placebo. An index of migraine activity was calculated from a daily record kept by the patient; it demonstrated a significant reduction in headache severity, duration, disability, and medication needed. Adverse effects were minimal and similar in drug and placebo. Naproxen is a promising agent in the prophylaxis of migraine.

Author Affiliations
From the Departments of Neurology, Kansas University Medical Center, Kansas City (Dr Ziegler), and Institute of Clinical Medicine, Syntex USA Inc, Palo Alto, Calif (Dr Ellis).

Footnotes
Accepted for publication June 11, 1984.

Reprint requests to Department of Neurology, Kansas University Medical Center, 39th and Rainbow Boulevard, Kansas City, KS 66103 (Dr Ziegler).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache
Snow et al.
ANN INTERN MED 2002;137:840-849.
ABSTRACT | FULL TEXT